Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the ​main goal of a mid- to late-stage ‌study, prompting it to pause enrollment in another ongoing study while it reassesses the program.